News

Prasco, as GlaxoSmithKline’s (GSK’s) agent and on GSK’s behalf, will solicit orders for, and distribute fluticasone propionate nasal spray to all trade classes in the US under a

Utilizing its flagship product, Ensemble for Life Science, ArtusLabs said that it created a system that combines access of structured, database-driven data with unstructured data in the same

“In 2008, we accomplished several key objectives on our path to delivering an effective treatment for severe sepsis for the U.S. market,” said Paul Walker, president and chief

SciClone Pharmaceuticals, a biopharmaceutical company, has completed enrollment ahead of schedule in the company’s Phase II clinical trial for RP101 in patients with late-stage pancreatic cancer. This study

Allscripts-Misys Healthcare Solutions, a provider of clinical software, connectivity and information solutions, has signed a definitive agreement to sell its medication services business to A-S Medication Solutions. Under

Acadia Pharmaceuticals, a developer of small molecule drugs for the treatment of central nervous system disorders, has reported a net loss of $14m, or $0.38 per share, for

Vivus, a biopharmaceutical company, has reported a net loss of $6.7m, or $0.10 per diluted share, for the fourth quarter of 2008, compared to a net income of

Interleukin Genetics, a genetics-focused personalized health company, has reported a net loss of $1.47m, or $0.05 per share, for the fourth quarter of 2008, compared to a net

This 12-week, randomized, double-blind, placebo-controlled, parallel group comparative study will evaluate the safety and efficacy of Avastrem in the treatment of tardive dyskinesia (TD). The primary objective of